The immune system was recognized in ancient times and rediscovered by Jenner and Pasteur based on its ability to confer protection against repeat exposure to a pathogen. Through subsequent studies by von Behring and others, it rapidly became apparent that the immune system has the potential to respond not only to whole microorganisms, but to virtually any molecule that is 'foreign' to the host. However, although injection of such molecules often provokes a robust immune response, this does not always occur. Immunization protocols improved in the 1920s with the discovery by Ramon and Glenny of immunostimulatory molecules (adjuvants) that could boost immune responses to coadministered antigens. Adjuvants were typically of microbial origin and became widely used to increase the effectiveness of immunizations. In the 1960s, Dresser showed that a highly purified foreign protein would only elicit an immune response if it was admixed with a microbial adjuvant 1 . If it was injected by itself, the foreign antigen not only failed to elicit immunity but actually induced a state of tolerance 2 . However, the significance of these observations was not well appreciated and adjuvants remained one of those things that everyone used simply because they were part of standard operating procedures.
In 1989, Janeway put these empirical observations into a conceptual framework 3 (FIG. 1) . He proposed that the immune system does not respond to all foreign antigens but only to those that are potentially associated with infection. The underlying idea to this model was that the immune system has evolved to protect the host against microorganisms and that this discrimination between infectious and non-infectious antigens focuses defences on real threats rather than innocuous situations.
At this time, it was already known that to stimulate T-cell responses, antigens had to first be acquired and presented on MHC molecules of an antigen-presenting cell (APC). Moreover, it was also known that APCs provide additional co-stimulatory signals necessary to activate T cells. Janeway incorporated these principles into his model (FIG. 1) . He postulated that the discrimination between infectious and non-infectious, non-self molecules is made by the APCs of the innate immune system through receptors that recognize pathogenassociated molecular patterns (PAMPs) made by microorganisms that are molecularly distinct from those made by mammals. PAMPs are naturally associated with infections and are the active ingredients of many adjuvants. Upon recognition of such molecules, the APCs are stimulated to express all of the signals required to activate naive T cells. This idea preceded the discovery of Toll-like receptors (TLRs) and other microbial sensors 4, 5 . We now know that Janeway's model is largely correct. However, it cannot explain all immune responses. In this article, we discuss the evidence supporting the concept that the immune system has also evolved mechanisms to sense primary and secondary necrotic cell death (which we refer to here simply as necrotic cell death) and respond to it with innate and adaptive immune responses. We highlight both what is known and what is as yet unknown about the mechanisms underlying these processes and how they might contribute to health and disease.
Adjuvants
These are immunostimulatory agents that enhance adaptive immune responses to coadministered antigens during vaccination.
Primary and secondary necrotic cell death
Primary necrosis (oncosis) is a form of cell death that is characterized by vacuolization of the cytoplasm and swelling of the mitochondria, nucleus and cytoplasm that leads to rupture of the plasma membrane. Secondary necrosis is a process that occurs in apoptotic cells that are not cleared by phagocytes, in which the integrity of the plasma membrane is lost and the constituents of the cell are released.
How dying cells alert the immune system to danger
Hajime Kono and Kenneth L. Rock Abstract | When a cell dies in vivo, the event does not go unnoticed. The host has evolved mechanisms to detect the death of cells and rapidly investigate the nature of their demise. If cell death is a result of natural causes -that is, it is part of normal physiological processes -then there is little threat to the organism. In this situation, little else is done other than to remove the corpse. However, if cells have died as the consequence of some violence or disease, then both defence and repair mechanisms are mobilized in the host. The importance of these processes to host defence and disease pathogenesis has only been appreciated relatively recently. This article reviews our current knowledge of these processes.
The danger hypothesis Janeway's hypothesis did not explain why robust T-cell immunity is generated in response to tissue transplants and some tumours, and also in autoimmune diseases, because these are all situations in which there is often no obvious microbial component (although in some cases, microorganisms might help to initiate these responses). Another possible exception to Janeway's model is certain viral infections, because all viral molecules are synthesized by the host and don't contain obvious features that distinguish them from host proteins (although it is now clear that there are molecular features of some viruses that are recognized by TLRs and other sensors such as helicases 6 ). Considering these exceptions led Matzinger to propose the danger hypothesis in 1994 (ReF. 7) (FIG. 1) . she postulated that the adaptive immune system evolved to respond not to infection per se but to non-physiological cell death, damage or stress. According to this idea, abnormal cell death is a potential threat to the organism whether it is caused by an infection or other pathological process, and it could be a universal sign of danger. This could explain how adaptive immune responses can be stimulated by both infectious and non-infectious agents, such as tumours and transplanted tissues, all situations in which necrotic cell death occurs. In the danger model, dying cells were postulated to release endogenous adjuvants that, using similar nomenclature to PAMPs, have been called damage-associated molecular patterns (DAMPs); for simplicity, we use this terminology here even though it is not clear whether endogenous danger signals really have distinctive molecular patterns as do PAMPs, although some have been proposed 8 . Although the term DAMP was originally introduced to describe damage-associated molecular patterns in all living organisms 8 , we use it here mainly to refer to danger signals of non-microbial origin. Like PAMPs, DAMPs have been proposed to activate local APCs to become stimulatory to the adaptive immune system.
The danger hypothesis was proposed entirely on theoretical grounds, and at the time of its conception, there was little experimental evidence to support its central tenets. It was known that cells by themselves, including dead ones, could be immunogenic 9 , but although such findings were consistent with the model, there was no direct evidence that cellular immunogens actually contained adjuvant activity. However, it was subsequently shown that when dead cells were admixed with an antigen and injected into animals, the dead cells increased antigen-specific CD4 + and CD8 + T-cell responses to the antigen 10, 11 . This was formal proof that dead cells contain endogenous adjuvants that promote T-cell immunity. It was also found that dead cells could stimulate dendritic cells (DCs) to mature into immunostimulatory cells in culture 10 and could promote the migration of mature DCs into draining lymph nodes in animals 12 .
When healthy cells were treated with proteinsynthesis inhibitors, their endogenous adjuvant activity was not decreased 11 . Moreover, when healthy cells were killed instantaneously by freeze-thawing, they provided adjuvant activity 10, 11 . Therefore, some or maybe even most DAMPs come from pre-existing molecules.
If DAMPs are pre-existing in cells, then how does the innate immune system distinguish dead cells from live ones? The crucial event upon necrotic cell death is thought to be the release of DAMPs from intracellular stores, which we refer to as the hidden self model (FIG. 2) . In support of this notion, cytosol obtained from healthy cells has adjuvant activity, which indicates that DAMPs are present intracellularly 11 . It is not yet clear whether there are also membrane-associated DAMPs, but nuclei have little adjuvant activity 11 . In living cells, , antigen-presenting cells (later appreciated to be DCs) were endowed with pattern-recognition receptors (PRRs) that recognize the unique features of microbial molecules (pathogen-associated molecular patterns, PAMPs). When PAMPs were present -for example, from an infection or adjuvant -then DCs were stimulated to migrate to lymphoid tissues and present both antigen and co-stimulatory molecules (CD80 and/or CD86) to T cells. In Matzinger's 'danger' model 7 , the crucial event controlling the initiation of an immune response was not infection, but the production of danger signals known as damage-associated molecular patterns (DAMPs) from cells stressed, damaged and/or dying in the local tissue. These were postulated to act on DCs in a manner that also caused them to migrate to lymphoid tissue and present antigens to T cells in an immunostimulatory manner. It has been speculated that DAMPs might be produced in response to PAMPs and therefore that DAMPs might be the final mediator promoting immune responses in all situations, including infection. This might occur; however, it is also possible, and in our view probable, that DAMPs and PAMPs can alert the immune system to a problem independently and possibly even in a synergistic manner. TCR, T-cell receptor. these intracellular DAMPs are normally sequestered from the innate immune system by the plasma membrane. However, when cells undergo necrosis they lose the integrity of their plasma membrane and release their intracellular contents, including the cytosolic DAMPs, into the extracellular milieu. This can also occur when apoptotic cells aren't rapidly cleared (FIG. 2) . so, the release of DAMPs into the extracellular environment functions as a sign of cell death to the innate immune system.
Danger and disease
The impetus for proposing the danger hypothesis was the observation that strong immune responses are generated in response to transplanted tissue and to tumours and in autoimmunity, all in the apparent absence of microbial infection. However, what is the evidence that cell death and/or specific DAMPs are involved in these responses? There are now an increasing number of examples in which cell death has been linked to the initiation of these immune responses.
In the case of autoimmunity, developmentally programmed death of pancreatic β-islet cells precedes the initiation of autoimmune diabetes in non-obese diabetic (NOD) mice
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. Preventing this cell death by treating noD mice with a caspase inhibitor blocked the subsequent development of autoimmunity 14 . similarly, when the death of β-islet cells is induced, autoimmune diabetes can be triggered 15 . such effects are not just limited to autoimmune diabetes. For example, injury to one eye can initiate an autoimmune response that destroys the contralateral eye, and ischemic necrosis of the heart can lead to autoimmune pericarditis 16, 17 . In the case of tumours, injection of dead cancer cells can stimulate T-cell responses 9 . Moreover, killing tumour cells with chemotherapeutic agents in vivo can also lead to increased T-cell immunity 18 . There is less direct evidence for this phenomenon in transplants, but it is clear that the greater the ischemic damage in an organ before it is transplanted, the more rapidly it is rejected 19 . The concept that cell death stimulates immune responses has often raised the question as to why cell injury and its attendant release of cell proteins and adjuvants does not lead to autoimmunity more frequently; that it does not is in fact not surprising
.
Although the observations described are consistent with the danger hypothesis, the fact that cell death helps to stimulate immune responses does not in itself prove that this is occurring through the release of DAMPs (as opposed, for example, to the exposure of cellular antigens). However, there is limited evidence that the depletion of one DAMP (uric acid, as discussed later) can decrease the activation of T cells to an autoantigen 20 , some cancers 21 and a transplanted cell line 20 . However, the loss of this DAMP did not completely inhibit these responses and for responses to some other transplanted tumours or tissues, the loss had no effect (A. Hearn, Y. shi, D. Greiner and K.L.R., unpublished observations). These incomplete effects are presumably the result of additional DAMPs that were not eliminated, although it cannot be ruled out that DAMPs have only a minor role in these responses. To determine the full contribution of danger signals to immune responses, it will be necessary to elucidate all of these DAMPs and then to test the effects of eliminating them. , that are normally hidden in the interior of cells and that are only revealed after necrosis. This model can explain why live cells, which contain pre-existing danger signals, don't stimulate the innate immune system. Moreover, it can also explain why necrotic cells always stimulate the innate immune system, whereas apoptotic cells are only stimulatory in some situations 99 and not in others
100
. This is because necrotic cells always lose membrane integrity and release their intracellular contents. By contrast, apoptotic cells initially maintain membrane integrity. If apoptotic cells are then rapidly cleared by phagocytes, the dead cells don't release their intracellular DAMPs and the immune system is not stimulated. However, if apoptotic cells are not rapidly cleared, as might occur in a solid organ, they undergo secondary necrosis and become permeable. The resulting release of DAMPs then stimulates the innate immune system. So, the event that communicates 'danger' to the immune system is not how the cell dies per se, but whether or not it eventually loses membrane integrity and releases its intracellular contents into the extracellular milieu. This concept of hidden signals being revealed might also apply to DAMPs of extracellular origin (for example, when revealed through the action of enzymes released after cell damage) and even, as has been proposed, hidden portions of molecules 8 .
DAMPs that function as adjuvants
In this Review, we restrict our discussion of DAMPs to host molecules that are not classical cytokines. Before reviewing specific DAMPs, it is important to discuss the criteria for establishing a candidate molecule as a bona fide DAMP. First, a DAMP should be active as a highly purified molecule. second, it is important to show that its biological activity is not owing to contamination with microbial molecules (PAMPs). such contaminants are easy to introduce, can co-purify by binding tightly to host molecules, and in many cases have similar immunostimulatory activities. Caution is particularly warranted if the putative DAMP is found to work through receptors for PAMPs, such as TLRs. Third, the DAMP should be active at concentrations that are actually present in pathophysiological situations. Fourth, selectively eliminating or inactivating the DAMP -for example, with antibodies, specific enzymes, targeted mutations or RnA interference (RnAi) -should ideally inhibit the biological activity of dead cells in in vitro and in vivo assays. of course, if the assay system is reading out several DAMPs with redundant activities, then this final criterion will be difficult to establish. As discussed here, these criteria have largely been met for only a few of the DAMPs that have been identified so far.
Heat-shock proteins. one of the first sets of endogenous cellular molecules that were described to have potential adjuvant properties were heat-shock proteins (HsPs). Injection of peptide-HsP complexes into animals was shown to promote immune responses to the bound antigenic peptide 22 . This effect was due, in part, to the ability of HsPs to target the associated peptides to APCs 22 . However, in addition, the HsPs seemed to provide an adjuvant activity as they could increase immune responses when admixed with antigens and injected into mice 23 . Moreover, purified HsPs have been shown to stimulate DCs to mature ex vivo 24 and also to stimulate these APCs to migrate to lymphoid organs in vivo 25 . However, it is controversial whether these immunostimulatory activities are due to the HsPs themselves. several studies have indicated that the immunostimulatory activities of HsPs are the result of contaminating microbial products, such as lipopolysaccharide (LPs) 26 , or other bioactive molecules (for example, concanavalin A) that are introduced during the purification procedure. experiments have not tested the effect of depleting HsPs on the adjuvant activity of dead cells; this is not a trivial experiment given the large number of different HsPs that might have to be eliminated. Therefore, the importance of HsPs as DAMPs is not yet clear.
Uric acid.
A second cellular molecule with adjuvant activity is uric acid. This was identified in a study that purified adjuvant activities for CD8 + T-cell responses from cells 27 . The active form of this molecule is thought to be monosodium urate (MsU) microcrystals that form when uric acid is released into the sodium-rich extracellular fluid. so, this is an example in which a DAMP becomes active by both release from an intracellular pool and a change in its structure. MsU crystals were shown to stimulate DCs in vitro and to have adjuvant activity in vivo. Importantly, the adjuvant activity of cells was decreased by enzymatic depletion of uric acid, which indicates that it is an important DAMP, at least in some cells 20, 27 . However, uric-acid depletion did not eliminate all endogenous adjuvant activity from dead cells and the cytosol was found to contain other activity 20, 27 , which indicates that there must be other important DAMPs.
HMGB1. The high-mobility group box 1 protein (HMGB1) also has adjuvant activity 28 . HMGB1 is an intracellular DnA-binding protein that stabilizes nucleosomes, has a role in bending DnA and regulates transcription. Certain viable leukocytes, such as DCs, can be stimulated to release HMGB1 by a non-classical secretion mechanism, and once in the extracellular fluid, this molecule functions as a cytokine 28 . Because HMGB1 was identified as a pro-inflammatory molecule released from necrotic cells 29 (see later), it was tested for adjuvant activity. When recombinant HMGB1 was added to immunizations with soluble antigen, it increased antibody responses, and for cellular antigens, it induced protection against tumour challenge 30 . In addition, supernatants from necrotic fibroblasts provided adjuvant activity when added to a tumour immunization, but when this necrotic supernatant came from HMGB1-deficient cells or was treated with a neutralizing antibody specific for HMGB1, its adjuvant activity was decreased by about 50%. This indicates that HMGB1 is an endogenous adjuvant, but not the only one in these cells 30 . HMGB1 was also shown to have a role in the tumour immunity that results from chemotherapy-and radiotherapy-induced cell death by selective inhibition with neutralizing antibodies or RnAi 31 . Consistent with its adjuvant activity in vivo, HMGB1 was found to stimulate cultured DCs to mature 30 . These data indicate that HMGB1 contributes to the endogenous adjuvant activity of at least some cells.
Genomic double-stranded DNA. Yet another molecule shown to have endogenous adjuvant activity is double-stranded (ds) genomic DnA. Mouse dsDnA stimulated cultured DCs to mature, although it did not
Box 1 | Danger and autoimmunity
If necrotic cell death releases endogenous adjuvants that promote immune responses to cellular antigens, then why doesn't autoimmune disease develop whenever there is cell injury? Indeed, it could also be asked why microbial infections, which contain potent microbial adjuvants, don't generally also stimulate autoimmune disease in response to cellular antigens released from damaged cells. The explanation might be that the host lacks autoreactive T cells that can respond to self antigens, either because they were deleted from the T-cell repertoire or are held in check by immunoregulatory mechanisms. In other words, adjuvants of either microbial or endogenous origin might be necessary, but they are not sufficient, to trigger immune responses. It is true that occasionally cell death and infections can trigger the development of autoimmune disease, but this is the exception rather than the rule. Where it has been studied, there is a strong multigenic component to several autoimmune diseases and although the underlying genetic defects are not fully understood, at least some of the diseaseassociated genes are involved in immunoregulatory processes 92 . So, it is possible that in individuals who are genetically predisposed to developing autoimmunity, microbial or endogenous adjuvants are sufficient to tip the balance and initiate disease. 
Cell death, DAMPs and inflammation
When cells die in vivo, the innate immune system not only alerts the adaptive immune system to potential danger, but also induces an inflammatory response 34 . In this process, mediators are generated that act on the local vasculature to cause arterioles to dilate and venules to leak fluid and recruit leukocytes from the blood into the tissue (FIG. 3) . The net effect of these processes is to increase blood flow and deliver protein-rich plasma and leukocytes to the site of injury. Grossly, this causes the signs and symptoms of redness, heat and swelling that are the hallmarks of an inflammatory response. The inflammatory response to cell death is robust and is so stereotypical that on pathological examination, the time of tissue injury can be established based on how far this response has progressed.
The inflammatory response to necrotic cell death was recognized long before the danger hypothesis was conceived. Although this response was not considered as part of the original danger hypothesis, we believe that it has a similar function and is best viewed as a component of the same overall process. so, as discussed earlier, necrotic cell death is potentially dangerous and in response to this threat, the innate immune system responds both directly with inflammation and also by calling in reinforcements from the adaptive immune system, such as pre-existing antibodies and complement (FIG. 3) . Although this is potentially useful for defence and repair, the host pays a price for marshalling the inflammatory response and it is one that can be quite costly
. Other molecules that are exposed or released from dead cells (such as proteases and hydrolases) act on extracellular components to generate mediators (for example, complement fragments) or DAMPs (for example, fragments of extracellular matrix) that then trigger the production of pro-inflammatory cytokines by host cells. The pro-inflammatory mediators act on local vascular endothelium, causing it to become 'leaky' and to attract neutrophils and monocytes/macrophages. Once in the tissue, these soluble (antibody) and cellular defences attempt to neutralize or contain microorganisms or other injurious agents if present. They also clear dead cells and stimulate tissue repair.
Galectins
These are lectins that bind a wide variety of glycoproteins and glycolipids containing β-galactoside. They have extracellular and intracellular functions, including the regulation of apoptosis, RAS signalling, cell adhesion and angiogenesis.
Natural IgM antibodies
Natural antibodies are present in individuals without immunization (although they might be stimulated by the host flora). They are mainly of the IgM isotype, have not undergone somatic mutations, and have low affinity but high crossreactivity for many microbial pathogens and self antigens.
that provide adjuvant activity, as discussed further later (TABLeS 1,2) . In fact, this overlapping activity could reflect a mechanistic link between inflammation and adjuvant effects. However, it is presently unknown whether all of the pro-inflammatory DAMPs have adjuvant activity and whether inflammation is always necessary for adjuvant activity. To answer these unresolved questions, it will be necessary to elucidate and characterize the various DAMPs.
There has been some progress recently in identifying pro-inflammatory DAMPs. They can be broadly subdivided into two categories on the basis of their origin and mechanism of action (FIG. 3) . In one class, the DAMPs are bioactive mediators of cellular origin that directly stimulate cells of the innate immune system. These structures are recognized by known or as-yet-unknown receptors. In the other class, molecules released from dead cells work more indirectly by generating DAMPs from other extracellular molecules (some might also work by activating extracellular mediators such as complement, which many would not consider to be DAMPs). The actual bioactive mediator in these cases comes from extracellular components. We consider each of these classes of DAMPs separately. Again, we restrict our discussion of DAMPs to host molecules that are not classical cytokines.
Intracellular pro-inflammatory DAMPs HMGB1, which was discussed in terms of its adjuvant properties earlier, was first identified as a DAMP based on its role in inducing inflammation 29 . HMGB1 released from necrotic cells was shown to stimulate monocytes in vitro to produce pro-inflammatory mediators 36 and injection of purified HMGB1 into mice stimulated an acute inflammatory response 37 . However, it is unclear whether all of these effects are due to HMGB1 itself or to an associated molecule.
HMGB1 binds tightly to certain molecules of microbial or cellular origin, and in some experiments, highly purified HMGB1 had little pro-inflammatory activity 38 . It is also not clear to what extent HMGB1 from dead cells contributes to the inflammatory response. After toxic or ischemic damage in the liver, treatment with HMGB1-specific antibodies decreases the ensuing inflammation, but only partially 29 . Although this indicates that HMGB1 has a role in these responses, it is uncertain whether the source of HMGB1 is from injured cells and/or from living leukocytes that secrete HMGB1 after activation. However, in a more direct test of this issue, injection of dead HMGB1-deficient fibroblasts stimulated inflammation as effectively as did HMGB1-sufficient cells 35 . Therefore, HMGB1 is not the only, or perhaps even the most important, pro-inflammatory DAMP released from dying cells.
Another DAMP with adjuvant activity that might also have a role in stimulating inflammation in response to dead cells is uric acid. As discussed earlier, cells contain high levels of uric acid that is released after necrotic cell death into the sodium-rich extracellular fluid and converted to MsU. It has long been known that when MsU crystals form spontaneously in patients with hyperuricaemia, they cause the acute inflammation of gout. Moreover, injection of pure MsU into animals or humans causes inflammation 39 . Therefore, the uric acid released from dead cells might contribute to initiating the ensuing inflammatory response.
Two other sets of molecules that have been shown to have pro-inflammatory activity both in vitro and in vivo are galectins and thioredoxin. Galectins are cytosolic lectins that can bind several cell-surface receptors, including CD2 and CD3 which can stimulate leukocytes 40 . They are expressed mainly by certain leukocytes and endothelial cells and therefore the potential contribution of galectins to inflammation would be limited to these cells. Thioredoxin is a ubiquitous intracellular enzyme with antioxidant activity 41 . Both galectins 42-44 and thioredoxin 45, 46 have been shown to stimulate various leukocytes and endothelial cells ex vivo and, when injected in vivo, to stimulate inflammation. To what extent these molecules actually contribute to the cell-death-induced inflammatory response, if at all, is unknown.
There are several other intracellular molecules that have been reported to stimulate the production of proinflammatory cytokines by leukocytes, mainly in in vitro experiments, and therefore are potential candidates for contributing to cell-death-induced inflammation. These include HsPs [47] [48] [49] [50] , s100 proteins 51, 52 , nucleosomes 53, 54 , purines such as ATP and adenosine 55, 56 , antimicrobial peptides [57] [58] [59] and N-formylated mitochondrial peptides 60 . The contribution of these molecules to celldeath-induced inflammation in vivo is also unknown.
Extracellular DAMPs and other mediators non-muscle myosin heavy chains (MYH9 and MYH14) are released from dead cells but are not themselves pro-inflammatory. However, normal animals have circulating natural IgM antibodies specific for these
Box 2 | Sterile inflammation and disease
Although the inflammatory response to cell death can neutralize or contain the underlying injurious process and promote tissue repair, it can also cause its own set of problems. The leukocytes that are recruited to an area of inflammation, particularly neutrophils, leak proteases and other noxious agents that can damage the surrounding viable tissue. This is evident from the finding that the amount of damage that occurs in ischemic injury of the heart 93 , lung 94 and skeletal muscle 95 and in toxic insults to the liver 96 and lung 97 was markedly decreased when neutrophils were acutely depleted with specific antibodies. Similar experiments have shown that neutrophil depletion can accelerate wound healing 98 . Moreover, blocking the signals that are required to generate acute neutrophilic inflammation in response to necrotic cell death (for example, the interleukin-1 receptor pathway) decreases the damage that occurs in response to drug-induced hepatocyte death 35 . Therefore, the collateral damage that occurs during inflammation in response to sterile tissue injury can be quite significant. Although this might be a reasonable price to pay to contain a serious threat such as an infection, it is much more costly when the inflammatory defence mechanisms aren't useful to combat the underlying cause of cell death. Consequently, the sterile inflammatory response is thought to underlie the pathogenesis of several acute and chronic diseases in which cell death has occurred (for example, ischaemia-reperfusion injury and chronic lung diseases). Given the importance of cell-death-induced inflammation to host defence and disease pathogenesis, it is important to understand how necrotic cell death stimulates inflammation and to identify molecular targets for therapeutic intervention. cellular proteins that bind the released myosin molecules 61 . The resulting immune complexes activate the complement cascade, leading to the generation of the pro-inflammatory complement fragments C3a, C4a and C5a. several findings indicate that this process is important for cell-death-induced inflammation, in at least some settings. Immunodeficient mice that lack antibodies have decreased inflammation in response to ischaemia-reperfusion injury of the bowel 62 , skeletal muscle 63 and heart 64 . Injection of a monoclonal myosin-heavy-chain-specific antibody into these animals restores the inflammatory response after injury 65 . Moreover, injection of a myosin peptide into normal (antibody-sufficient) mice to block their natural myosin-specific antibodies inhibits the inflammatory response to ischaemia-reperfusion injury 61 . Therefore, the non-muscle myosins can trigger an extracellular inflammatory pathway. several molecules are exposed or released upon necrotic cell death that trigger the generation of extracellular pro-inflammatory molecules (TABLe 2) . These include cellular molecules that directly activate the complement cascade 66, 67 or cleave extracellular matrix molecules such as collagen 68, 69 , fibrillar protein 70 , hyaluronic acid 71 and heparan sulphate 72 into pro-inflammatory fragments. Cellular molecules can also trigger the clotting, fibrinolytic and kinin cascades, which generate other pro-inflammatory mediators 73 . The cellular molecules that are responsible for these effects are not known, but they are presumably various hydrolases and proteases. The extent to which these cellular triggers and the extracellular DAMPs that they help generate contribute to the inflammatory response to dead cells is not clear.
Receptors for DAMPs
Much more is known about how the innate immune system senses microbial PAMPs than about how it recognizes DAMPs. In the case of extracellular PAMPs, some of the most important sensors are TLRs 74, 75 . As PAMPs and DAMPs both have adjuvant and pro-inflammatory properties, one possibility is that they work through the same receptors 74 . A potential role for TLRs in the recognition of DAMPs has been explored so far mainly in inflammatory responses stimulated by dead cells and selected DAMPs (TABLeS 1,2) .
experiments involving the injection of dead cells into TLR-deficient mice have shown that no single TLR examined so far is required for the inflammatory response, although TLR5 and TLR8 were not analysed 35 . similarly, mice lacking Toll/interleukin-1 receptor (TIR) domain-containing adaptor molecule 2 (TICAM2), a signalling adaptor protein that is used by TLR3 and TLR4, have normal inflammatory responses to dead cells. By contrast, mice that were deficient in both TLR2 and TLR4 had decreased inflammation, but the magnitude of this effect was quite small 35 . Celldeath-induced neutrophilic inflammation was markedly decreased in mice lacking myeloid differentiation primary response gene 88 (MYD88), a signalling adaptor protein that is required downstream of all TLRs (except TLR3) as well as the interleukin-1 (IL-1) and IL-18 receptors. However, this effect was mainly due to a crucial role for the IL-1 receptor in the recruitment of neutrophils 35 . Therefore, it seems that TLRs, and in particular TLR2 and TLR4, might have only a small role in the cell-death-induced inflammatory response. several purified DAMPs have been reported to stimulate TLR2 and TLR4. These include HMGB1 31,76 , uric acid 77 , some HsPs 78, 79 , some defensins 80 , hyaluronic acid 81 , heparan sulphate 82 and some fragments of extracellular matrix proteins 70 . Although these data might be correct, caution is warranted because TLRs can be stimulated by microbial contaminants that are easily introduced during the purification of DAMPs. Perhaps such contaminants explain why there are also conflicting data showing that some of these same DAMPs (including uric acid 83, 84 , HsPs 85 and HMGB1 86 ) do not stimulate responses through TLR2 or TLR4.
In addition to TLRs, some other receptors have been implicated in the actions of various DAMPs (TABLeS 1,2) . RAGe (receptor for advanced glycation end-products; also known as AGeR) binds HMGB1 and s100 proteins and has been reported to mediate the adjuvant 87 and pro-inflammatory effects 51 Clearly, much more work is required to elucidate the receptors involved in sensing DAMPs. This is an important issue not only for understanding how cell death is perceived by the innate immune system, but also because the nature, diversity and distribution of these receptors will determine the nature of the pathophysiological responses that are stimulated by necrotic cell death; these receptors might also be molecular targets for therapeutic intervention.
Conclusions
Cell death is potentially dangerous to the host and therefore the immune system has evolved mechanisms to detect and respond to this process. It accomplishes this important task by having the innate immune system monitor tissues for cells that are disintegrating. Upon detecting the release of intracellular contents, an inflammatory response is rapidly mobilized. This provides initial defence and also attempts to clear and repair the damage. In parallel, DCs are stimulated to mature and induce adaptive immune responses if immunogenic antigens are present. Collectively, these responses help to protect the host and limit the injurious process, but can themselves also cause tissue damage and disease. There are several important unresolved issues in understanding these responses. For example, the number of different danger signals, their molecular identity, and whether different ones have different biological effects are not known. similarly, the receptors and pathways that sense the release of these signals need to be better elucidated. once the molecular participants are identified, it will be necessary to define their roles in both health and disease. Ultimately, it might be possible to use these molecules to manipulate immune responses (for example, as vaccine adjuvants) or to inhibit them to treat autoimmune or inflammatory diseases.
